DV
Dividend Vision

ZNTL — Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc. (ZNTL)

Total return is -84.7% over the past 6.4 years, 325.9 points behind SPY at 241.2%. Its deepest 1-year drawdown was 46.7%.

Zentalis Pharmaceuticals is a single-stock equity holding focused on a biopharmaceutical company engaged in clinical-stage drug development. The security does not currently pay distributions and carries no dividend yield, making it unsuitable for income-focused investors seeking regular cash returns. This holding appeals primarily to growth-oriented investors seeking exposure to the biotechnology sector's potential for capital appreciation rather than current income generation.

ZNTL key facts

Asset type
Stock
Asset class
Equity
Inception date
04/03/2020
Distribution frequency
None
Last close
$3.56
Market cap
$255,152,000
Average volume
4575200.0
Beta
1.891
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.96